He didn't want to talk about his dad.
He wanted to talk about p53.
Meet Reed Jobs — yes, that Jobs — and the venture firm he's built to go after cancer's most unkillable targets.
Three years ago, Yosemite was a brand-new idea born into a crashed biotech market.
Today?
It's chasing $350 million for its second fund, running 25 portfolio companies, and moving faster than even its founder expected.
Most VCs wait for hot deals to walk in the door.
Yosemite goes the other way.
Two of their companies came directly out of a grant.
That's not typical venture math. That's a different bet entirely.
For decades, KRAS was nicknamed the Death Star.
Smooth. No handle. No way in.
Then AI helped scientists find a crack.
👉 Revolution Medicines' KRAS drug just doubled survival in the deadliest pancreatic cancer — from 12 months to 24.
That happened in the last year alone.
Now Yosemite has three companies chasing an even bigger prize: p53, the gene almost every cancer has to disable to survive.
Fun fact hiding in plain sight — elephants barely get cancer because they carry dozens of backup copies of p53. Humans get just one.
Turn it back on, and you may have found cancer's actual Achilles' heel.
Even the NIH threat cooled — a proposed 40% budget cut got rejected outright last year, bipartisan and unanimous.
Jobs isn't chasing headlines with a famous surname.
He's chasing the genes nobody else could touch.
And for the first time in decades, they're starting to move.
That's all for now!
